Canngea
Mikayla W. currently serves as the Medical Relations Director at Canngea since June 2024. Prior to this role, Mikayla worked as a Medicinal Cannabis Pharmacist at DUKASA COMPOUNDING from January 2023 to April 2024, focusing on innovative cannabinoid medicines and plant-based therapies. Mikayla's experience also includes two internships at Peninsula Private Hospital and DUKASA COMPOUNDING between January 2021 and December 2022. Mikayla completed a Bachelor of Pharmacy (Honours) at RMIT University from January 2020 to December 2021 and previously attended Curtin University for the same degree from January 2018 to December 2019.
This person is not in the org chart
This person is not in any teams
Canngea
Canngea Pty Ltd was incorporated in Sydney, Australia in 2017. Our mission is to bridge the gap between ancient and contemporary medicine for a better quality of life, and our vision is to be the leading medical cannabis manufacturer, storage and wholesale distributor in Australia. Canngea sources and supplies: GMP approved white and private label formulation products; GACP & GMP dried flower products; Raw API materials (Active Pharmaceutical Ingredients) including THC distillates, biomass flower and CBD isolates. Canngea operates globally in partnership with S4 and S8 storage and distributors, manufacturers, cultivators and brand owners; as well as researchers and developers including the University of Sydney. We are committed to undertaking research and development (R&D) activities that can bring additional value to our business partners. We have a strategic partnership to facilitate R&D activities, through our Science Director Dr Nial Wheate with the School of Pharmacy at The University of Sydney, where Dr Wheate is also an Associate Professor. We are proud members of the leading industry associations Australian Medicinal Cannabis Association (AMCA) and API Manufacturers Association of Australia (APIMAA).